<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clinical manifestations, diagnosis, and treatment of nephronophthisis</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clinical manifestations, diagnosis, and treatment of nephronophthisis</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Clinical manifestations, diagnosis, and treatment of nephronophthisis</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Patrick Niaudet, MD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Tej K Mattoo, MD, DCH, FRCP</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Ronald D Perrone, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Alison G Hoppin, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Apr 30, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H3634494387"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Nephronophthisis (NPHP) is a clinical condition caused by a group of autosomal recessive cystic kidney disorders that typically progresses to end-stage kidney disease (ESKD). It is caused by variants in a large number of genes that encode proteins involved in the function of primary cilia, basal bodies, and centrosomes, resulting in kidney disease and extra-renal manifestations including retinal degeneration, cerebellar ataxia, and liver fibrosis.</p><p>The clinical manifestations and management of NPHP will be reviewed here. The genetics and pathogenesis of NPHP are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/6136.html" rel="external">"Genetics and pathogenesis of nephronophthisis"</a>.)</p><p class="headingAnchor" id="H1715235936"><span class="h1">OVERVIEW</span><span class="headingEndMark"> — </span>Patients with NPHP have gene variants that encode components of the ciliary apparatus (centrosome, basal bodies, and primary cilia) [<a href="#rid1">1,2</a>]. The gene defects result in the following characteristic findings of NPHP (see  <a class="medical medical_review" href="/z/d/html/6136.html" rel="external">"Genetics and pathogenesis of nephronophthisis"</a>):</p><p class="bulletIndent1"><span class="glyph">●</span>Autosomal recessive inheritance.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Impaired urinary concentrating ability and sodium reabsorption, resulting in polyuria, polydipsia, and secondary enuresis [<a href="#rid3">3-5</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Urine sediment is typically bland with absence of red blood cells and cellular casts – Proteinuria is often absent, although some patients may show mild tubular proteinuria in early stages of the disease and glomerular proteinuria at late stages with evidence of chronic kidney disease (CKD). </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Chronic tubulointerstitial nephropathy and progression to end-stage kidney disease (ESKD).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Extra-renal manifestations consistent with ciliary pathology in 20 percent of patients.</p><p></p><p>Three clinical variants have been described based upon the median age of onset of ESKD [<a href="#rid6">6,7</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Infantile − 1 year of age</p><p class="bulletIndent1"><span class="glyph">●</span>Juvenile − 13 years of age</p><p class="bulletIndent1"><span class="glyph">●</span>Adolescent − 19 years of age</p><p></p><p>These clinical variants are associated with variants of specific genes. In addition, extra-renal manifestations (eg, retinitis pigmentosa) are present in 20 percent of cases and are usually also associated with a specific gene defect. (See <a class="local">'Extrarenal manifestations'</a> below.)</p><p class="headingAnchor" id="H2"><span class="h1">CLINICAL MANIFESTATIONS</span><span class="headingEndMark"> — </span>NPHP is characterized by the insidious onset of end-stage kidney disease (ESKD). Extra-renal manifestations are present in 20 percent of patients, including retinitis pigmentosa, hepatic fibrosis, and skeletal defects [<a href="#rid1">1,8</a>]. </p><p>NPHP is a major clinical finding in several syndromes, including Senior-Loken, Joubert, Meckel-Gruber, Cogan, and Sensenbrenner syndromes and asphyxiating thoracic dystrophy (ATD; also known as Jeune syndrome). (See <a class="local">'Associated syndromes'</a> below.)</p><p class="headingAnchor" id="H3"><span class="h2">Renal disease</span><span class="headingEndMark"> — </span>NPHP almost always progresses to ESKD, primarily before 20 years of age [<a href="#rid6">6,9</a>]. However, there have been case reports of patients who progressed to ESKD between the ages of 27 and 56 years [<a href="#rid1">1,10-12</a>]. In two patients, severe visual impairment due to retinal dystrophy presented in childhood preceding evidence of impaired kidney function. The clinical variants are classified based on the expected age for ESKD  (<a class="graphic graphic_table graphicRef128963" href="/z/d/graphic/128963.html" rel="external">table 1</a>). (See  <a class="medical medical_review" href="/z/d/html/6136.html" rel="external">"Genetics and pathogenesis of nephronophthisis", section on 'Genetics'</a>.) </p><p>As chronic kidney disease (CKD) progresses, patients develop anemia, metabolic acidosis, and early uremic symptoms such as nausea, anorexia, and weakness. Unlike other conditions that progress to CKD, most patients with NPHP remain normotensive. Normal blood pressure is most likely due to hypovolemia caused by impaired urinary concentration and renal salt wasting [<a href="#rid3">3,5</a>]. In these patients, there is typically no proteinuria or mild tubular proteinuria in early stages of the disease, no hematuria, and no cellular elements. In late stages of the disease, glomerular proteinuria may develop due to secondary glomerulosclerosis [<a href="#rid6">6</a>]. (See  <a class="medical medical_review" href="/z/d/html/6134.html" rel="external">"Chronic kidney disease in children: Clinical manifestations and evaluation"</a>.)</p><p>The rate of progression to ESKD is determined in part by the type and severity of the genetic defect. Among the identified <em>NPHP</em> genes, four of them account for 75 percent of identified disease-causing variants, namely <em>NPHP1, NPHP3, NPHP4</em> and <em>NPHP11/TMEM67</em>. Kidney survival was analyzed in 383 individuals with variants in one of these genes [<a href="#rid13">13</a>]. Median age at onset of ESKD was as follows: </p><p class="bulletIndent1"><span class="glyph">●</span><em>NPHP3</em>, 4 years (interquartile range 0.3 to 12)</p><p class="bulletIndent1"><span class="glyph">●</span><em>NPHP1</em>, 13.5 years (interquartile range 10.5 to 16.5)</p><p class="bulletIndent1"><span class="glyph">●</span><em>NPHP4</em>, 16 years (interquartile range 11 to 25)</p><p class="bulletIndent1"><span class="glyph">●</span><em>NPHP11/TMEM67</em>, 19 years (interquartile range 8.7 to 28) </p><p></p><p>Kidney survival was significantly associated with the underlying variant type f<em>or NPHP1, NPHP3,</em> a<em>nd NPHP4</em>. </p><p class="headingAnchor" id="H2952264336"><span class="h3">Infantile</span><span class="headingEndMark"> — </span>Infantile NPHP is rare and is the most severe form of NPHP [<a href="#rid1">1,14,15</a>]. Affected children develop ESKD between birth and three years of age (median age of one year). This form may present prenatally with a history of oligohydramnios. Unlike the other variants of NPHP, severe hypertension is common [<a href="#rid1">1,16</a>]. Prenatal ultrasound may detect kidney abnormalities by 22 weeks gestation [<a href="#rid17">17</a>]. Renal ultrasound demonstrates hyperechogenic kidneys that vary in size (large to small) and cortical microcysts [<a href="#rid18">18</a>].</p><p>Extra-renal findings are more common in patients with infantile NPHP compared with later-onset forms, occurring in approximately 80 percent of patients and includes hepatic involvement (50 percent), cardiac valve or septal defects (20 percent), and recurrent bronchial infections (18 percent) [<a href="#rid18">18</a>].</p><p>Infantile NPHP is typically caused by variants in the <em>NPHP2 </em>and <em>NPHP3 </em>genes [<a href="#rid18">18</a>]. Variants of the <em>NPHP2</em> gene, which encodes the protein inversin (also referred to as nephrocystin-2), are also often associated with situs inversus. (See  <a class="medical medical_review" href="/z/d/html/6136.html" rel="external">"Genetics and pathogenesis of nephronophthisis", section on 'NPHP2 gene'</a> and  <a class="medical medical_review" href="/z/d/html/6136.html" rel="external">"Genetics and pathogenesis of nephronophthisis", section on 'NPHP3 gene'</a>.) </p><p class="headingAnchor" id="H2973855628"><span class="h3">Juvenile</span><span class="headingEndMark"> — </span>The most common form of NPHP is the juvenile variant. The clinical symptoms include polyuria, polydipsia, and secondary enuresis occurring at age of four to six years. These findings are due to tubular dysfunction resulting in impaired urinary concentrating ability and sodium reabsorption. Blood pressure usually is normal, in contrast to the infantile variant, in which hypertension is common. These patients develop ESKD by a median age of 13 years [<a href="#rid1">1,2,8</a>]. </p><p></p><p>In affected children, even after a period of fluid restriction, urinary osmolality will remain low (&lt;400 mosmol/kg) and is not increased by the administration of <a class="drug drug_pediatric" data-topicid="12876" href="/z/d/drug information/12876.html" rel="external">vasopressin</a> (see  <a class="medical medical_review" href="/z/d/html/2381.html" rel="external">"Evaluation of patients with polyuria"</a>) [<a href="#rid6">6,19</a>]. Sodium wasting can lead to hypovolemia, hyponatremia, and an elevation in the plasma creatinine concentration if sodium intake is diminished [<a href="#rid3">3-5</a>]. These abnormalities precede any decline in glomerular filtration rate (GFR).</p><p>Poor growth may be initially related to chronic hypovolemia and later due to growth retardation secondary to CKD. Anemia due to erythropoietin (which is secreted by interstitial fibroblasts) deficiency may be a presenting finding of tubulointerstitial involvement prior to a significant decline in GFR [<a href="#rid6">6,20</a>]. </p><p>Ultrasonography demonstrates normal or slightly decreased-in-size kidneys with increased echogenicity and loss of corticomedullary differentiation [<a href="#rid21">21</a>]. There is no dilation of the urinary tract, and renal cysts are not typically identified on the initial ultrasound examination, but may appear at a later stage of the disease [<a href="#rid22">22</a>].</p><p>The juvenile form of the disease is primarily due to <em>NPHP1</em> gene variants, which are the most common genetic defect associated with NPHP [<a href="#rid2">2,8</a>]. However, variants have been reported in all genes except the <em>NPHP2</em> gene in patients with juvenile NPHP [<a href="#rid23">23,24</a>]. (See  <a class="medical medical_review" href="/z/d/html/6136.html" rel="external">"Genetics and pathogenesis of nephronophthisis", section on 'Genetics'</a>.)</p><p class="headingAnchor" id="H1160349510"><span class="h3">Adolescent</span><span class="headingEndMark"> — </span>Most patients with <em>NPHP3 </em>gene variants develop ESKD in late adolescence and young adulthood, with a reported median age of 19 years (range 4 to 37 years) at the time of ESKD [<a href="#rid23">23,24</a>]. Patients will also exhibit initial symptoms of polyuria and polydipsia due to reduced urinary concentrating ability and renal salt wasting but at a later age than those with the juvenile variant.</p><p class="headingAnchor" id="H73561562"><span class="h2">Extrarenal manifestations</span><span class="headingEndMark"> — </span>Extra-renal manifestations reflect multisystem disease due to ciliary dysfunction and occur in approximately 20 percent of patients with NPHP. They are often seen in syndromic NPHP (see <a class="local">'Associated syndromes'</a> below) and include the following [<a href="#rid1">1,25</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Skeletal defects</strong> − Several skeletal defects have been associated with NPHP, including shortening of the limbs and ribs, scoliosis, polydactyly, brachydactyly, craniosynostosis, and cone-shaped epiphyses of the phalanges. The association of cone-shaped epiphyses with NPHP is known as the Mainzer-Saldino syndrome  (<a class="graphic graphic_diagnosticimage graphicRef118301" href="/z/d/graphic/118301.html" rel="external">image 1</a>) [<a href="#rid26">26</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Eye</strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Visual impairment due to retinitis pigmentosa [<a href="#rid27">27</a>] (also referred to as tapetoretinal degeneration  (<a class="graphic graphic_picture graphicRef62898" href="/z/d/graphic/62898.html" rel="external">picture 1</a>)) is seen in patients with Senior-Loken syndrome and Leber congenital amaurosis. Retinitis pigmentosa is observed in 10 to 15 percent of patients with NPHP, particularly in patients with variants in the <em>NPHP1</em>, <em>NPHP2</em>, <em>NPHP3</em>, and <em>NPHP4</em> genes. Retinal coloboma can be observed in patients with Joubert syndrome [<a href="#rid28">28</a>]. (See <a class="local">'Senior-Loken syndrome and retinitis pigmentosa'</a> below and  <a class="medical medical_review" href="/z/d/html/6905.html" rel="external">"Retinitis pigmentosa: Clinical presentation and diagnosis"</a>.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Oculomotor apraxia seen in Cogan syndrome is less common and is characterized by impaired horizontal voluntary eye movements and nystagmus [<a href="#rid27">27</a>]. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Nystagmus and ocular coloboma are seen in patients with the Joubert syndrome.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Neurologic</strong> – In addition to the abnormal ophthalmologic findings, significant neurologic abnormalities are often observed in children who present with NPHP as a syndromic component (eg, Joubert syndrome). These include cerebral ataxia, hypotonia, and severe developmental delay.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Liver</strong> − Hepatic involvement may be characterized by hepatosplenomegaly, congenital hepatic fibrosis, and portal fibrosis without or with mild bile duct proliferation [<a href="#rid23">23,29-32</a>]. Liver anomalies have been reported in patients with variants in the genes <em>NPHP3</em>, <em>NPHP11</em>, <em>TMEM67</em>, <em>ANKS6</em>, and <em>DCDC2</em> [<a href="#rid23">23,32-34</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Situs inversus</strong> − Situs inversus has been reported in patients with variants in <em>NPHP2,</em> <em>NPHP3, </em>and<em> ANKS6 </em>genes [<a href="#rid15">15,18,33</a>]. (See  <a class="medical medical_review" href="/z/d/html/6136.html" rel="external">"Genetics and pathogenesis of nephronophthisis", section on 'Genetics'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Cardiac</strong> – Ventricular septal and valve defects have been reported in patients with <em>NPHP2</em> and <em>NPHP3</em> variants [<a href="#rid15">15,18,35</a>].</p><p></p><p class="headingAnchor" id="H73561245"><span class="h2">Associated syndromes</span><span class="headingEndMark"> — </span>Syndromes associated with ciliary dysfunction and NPHP include Senior-Loken, Joubert, Meckel-Gruber, and Sensenbrenner syndromes, and ATD [<a href="#rid36">36</a>]. The term NPHP-related ciliopathies (NPHP-RC) is used for this group of autosomal-recessive cystic kidney diseases. </p><p class="headingAnchor" id="H4"><span class="h3">Senior-Loken syndrome and retinitis pigmentosa</span><span class="headingEndMark"> — </span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fghr.nlm.nih.gov%2Fcondition%2Fsenior-loken-syndrome&amp;token=XjQim5%2BEej8xBeKbxHBrn7ldhyNeQtEUu7%2F0oh8eAxjO8tCNVfbLP8PP3rAZPz%2BEcpZx2TqCxktm%2B31CzAifkQ%3D%3D&amp;TOPIC_ID=6132" target="_blank">Senior-Loken syndrome (OMIM #266900)</a> is characterized by the concomitant presentation of retinitis pigmentosa with severe visual loss (also referred to as tapetoretinal degeneration  (<a class="graphic graphic_picture graphicRef62898" href="/z/d/graphic/62898.html" rel="external">picture 1</a>)) and NPHP [<a href="#rid37">37,38</a>]. Although this syndrome is observed in association with variants in most of the NPHP genes, variants of the <em>NPHP5</em> and <em>NPHP6 </em>genes are the most common [<a href="#rid39">39</a>]. All patients with variants of these two genes have retinitis, which occurs early in life and is more severe than in patients with variants in other <em>NPHP</em> genes. In children with variants in the <em>NPHP1, NPHP2, NPHP3, </em>and<em> NPHP4</em> genes, retinitis pigmentosa occurs in approximately 10 percent of families, and the kidney course of NPHP is similar in patients with and without ocular involvement [<a href="#rid6">6,40,41</a>]. (See  <a class="medical medical_review" href="/z/d/html/6136.html" rel="external">"Genetics and pathogenesis of nephronophthisis", section on 'Genetics'</a>.)</p><p class="headingAnchor" id="H6"><span class="h3">Joubert syndrome</span><span class="headingEndMark"> — </span><a class="external" href="/external-redirect?target_url=https%3A%2F%2Fghr.nlm.nih.gov%2Fcondition%2Fjoubert-syndrome&amp;token=BfoxipVwzLU7TCgREeSaqAfJBt%2BqlE9j8gXYymLNbRDZYdaojRur17eip8SlLxY%2F1IVqYpMerla3PsD5mfE6Hg%3D%3D&amp;TOPIC_ID=6132" target="_blank">Joubert syndrome (OMIM #213300)</a> is an autosomal recessive neurologic disorder characterized by cerebellar vermis hypoplasia resulting in ataxia, polydactyly, hypotonia, developmental delay, neonatal respiratory dysregulation, and abnormal eye movements [<a href="#rid42">42,43</a>]. NPHP or cystic kidney dysplasia is seen in approximately one-fourth of cases [<a href="#rid44">44</a>]. A pathognomonic finding on axial magnetic resonance imaging (MRI) of the brain is the presence of prominent superior cerebellar peduncles, referred to as "molar tooth sign" of the midbrain-hindbrain junction  (<a class="graphic graphic_diagnosticimage graphicRef74695" href="/z/d/graphic/74695.html" rel="external">image 2</a>) [<a href="#rid45">45</a>].</p><p>Joubert syndrome can be associated with juvenile NPHP and/or retinal involvement (Joubert syndrome type B). Several loci for Joubert syndrome associated with NPHP have been isolated, suggesting genetic heterogeneity [<a href="#rid21">21,22,42-44,46-53</a>].</p><p>Oculomotor apraxia with cerebellar vermis aplasia has also been reported in Joubert syndrome, which may be challenging to distinguish from Cogan syndrome [<a href="#rid54">54</a>].</p><p class="headingAnchor" id="H7"><span class="h3">Meckel-Gruber syndrome</span><span class="headingEndMark"> — </span>Variants in the <em>NPHP3,</em> <em>NPHP6, NPHP8</em>, and <em>MKS</em> genes can cause <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fghr.nlm.nih.gov%2Fcondition%2Fmeckel-syndrome&amp;token=tL%2Bd%2BvL9iBbgDZVesCc9yXN9rBklnSaFoEnA9Hi9qP4Wf6%2B8LWv43cR0DTq66qGBYxR9Vgq4h8XBGSxh%2FNRLQA%3D%3D&amp;TOPIC_ID=6132" target="_blank">Meckel-Gruber</a>, an autosomal recessive lethal disorder characterized by central nervous system (CNS) malformation (eg, occipital encephalocele), bilateral renal cystic dysplasia, cleft palate, polydactyly, ductal proliferation in the portal area of the liver, pulmonary hypoplasia, and situs inversus [<a href="#rid35">35,55,56</a>]. Meckel-Gruber syndrome is lethal in early life.</p><p class="headingAnchor" id="H18853731"><span class="h3">Asphyxiating thoracic dystrophy</span><span class="headingEndMark"> — </span>Asphyxiating thoracic dystrophy (ATD, also called Jeune syndrome) are autosomal recessive disorders characterized by skeletal dysplasia with multiorgan involvement. Variants in four genes have been identified: <em>IFT80</em>, <em>DYNC2H1</em>, <em>TTC21B</em>, and <em>WDR19</em>. Variants in the <em>TTC21B</em> gene, which encodes the retrograde intraflagellar transport protein IFT139, are associated with isolated NPHP and ATD [<a href="#rid48">48</a>]. (See  <a class="medical medical_review" href="/z/d/html/4320.html" rel="external">"Chest wall diseases and restrictive physiology", section on 'Asphyxiating thoracic dystrophy'</a>.)</p><p class="headingAnchor" id="H359589346"><span class="h3">Sensenbrenner syndrome</span><span class="headingEndMark"> — </span>Sensenbrenner syndrome, also called <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fghr.nlm.nih.gov%2Fcondition%2Fcranioectodermal-dysplasia&amp;token=KrK9d2cTgKoJColwpnOdCspu6NkGvuboJ5vbV%2Bz%2BWSo47tf0H6aISj5QMM4bDPlK8IhixMkp0uz7ZhkL6cCmcg%3D%3D&amp;TOPIC_ID=6132" target="_blank">cranioectodermal dysplasia</a>, is an autosomal recessive ciliary disorder of the skeleton characterized by craniosynostosis, short limbs, brachydactyly, narrow thorax, and facial anomalies. Some patients have NPHP, retinitis pigmentosa, hepatic fibrosis, and brain anomalies [<a href="#rid49">49</a>]. Variants in four different genes have been reported in Sensenbrenner syndrome: <em>IFT122</em>, <em>WDR35</em>, <em>IFT43</em>, and <em>WDR19</em>. (See  <a class="medical medical_review" href="/z/d/html/108252.html" rel="external">"Skeletal dysplasias: Specific disorders", section on 'Sensenbrenner syndrome'</a>.)</p><p class="headingAnchor" id="H10"><span class="h1">DIAGNOSIS</span><span class="headingEndMark"> — </span>The diagnosis of NPHP is suggested by characteristic clinical findings and confirmed by a positive genetic test. In the absence of a positive gene test, a kidney biopsy demonstrating chronic tubulointerstitial changes with a thickening of tubular basement membranes is suggestive of the diagnosis  (<a class="graphic graphic_picture graphicRef66242" href="/z/d/graphic/66242.html" rel="external">picture 2</a>). </p><p class="headingAnchor" id="H413519214"><span class="h2">Clinical diagnosis</span><span class="headingEndMark"> — </span>The clinical characteristics suggestive of NPHP vary by age  (<a class="graphic graphic_table graphicRef128963" href="/z/d/graphic/128963.html" rel="external">table 1</a>). However, regardless of age, the suspicion of a diagnosis of NPHP increases for a child with kidney disease who also presents with an associated extra-renal manifestations (retinal disease, abnormal ocular eye movements, ataxia, cardiac malformations, skeletal and neurologic abnormalities, and situs inversus). (See <a class="local">'Clinical manifestations'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span>Infantile – NPHP should be considered in any infant and young child (&lt;5 years of age) who presents with end-stage kidney disease (ESKD), severe hypertension, and extra-renal anomalies [<a href="#rid18">18</a>]. (See <a class="local">'Infantile'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>NPHP should be considered in older children and adolescents who present with the following (see <a class="local">'Juvenile'</a> above and <a class="local">'Adolescent'</a> above):</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Polyuria and polydipsia, which often manifest as primary enuresis due to decreased urinary concentrating ability.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Progressive chronic kidney disease (CKD) with normal blood pressure.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Bland urinalysis (absence of proteinuria or mild tubular proteinuria, absence of hematuria and cellular elements).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Normal or slightly decreased-in-size kidneys with increased echogenicity, reduced corticomedullary differentiation, and renal cysts on ultrasound examination.</p><p></p><p>In some cases, a clinical diagnosis can be made in a child with characteristic findings of NPHP, including ultrasonography compatible with NPHP and extra-renal manifestations that are known to be associated with NPHP, such as retinitis pigmentosa as seen in patients with Senior-Loken syndrome. (See <a class="local">'Associated syndromes'</a> above.)</p><p class="headingAnchor" id="H1563288230"><span class="h2">Genetic testing</span><span class="headingEndMark"> — </span>Molecular genetic screening allows gene identification in 50 to 70 percent of NPHP cases. If available, we suggest genetic testing using high-throughput exon sequencing and whole-exome sequencing for any patient in whom there is a clinical diagnosis of NPHP [<a href="#rid57">57,58</a>].</p><p>If a whole-exome sequencing panel is not available, testing can be performed for individual genes. In patients in whom there is a high clinical suspicion for NPHP, screening for homozygous or heterozygous <em>NPHP1</em> deletion should be performed as these variants are the most common. </p><p>Other gene variants are responsible for less than 3 percent of cases each. Based upon the clinical manifestations of individual patients, testing of specific genes may be performed  (<a class="graphic graphic_table graphicRef90846" href="/z/d/graphic/90846.html" rel="external">table 2</a>):</p><p class="bulletIndent1"><span class="glyph">●</span><em>NPHP5</em> gene in cases of severe retinitis pigmentosa</p><p class="bulletIndent1"><span class="glyph">●</span><em>NPHP6</em> and <em>NPHP8</em> genes in patients with neurological symptoms</p><p class="bulletIndent1"><span class="glyph">●</span><em>NPHP2</em> and <em>NPHP3</em> genes in cases of early onset of CKD [<a href="#rid18">18</a>]</p><p></p><p>Information regarding genetic testing for NPHP is available at <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.renalgenes.org%2F&amp;token=twcGxy%2F8D9pHAGbYCyoWKwdeF9yxcqC7jcU3qggqdaFwipUBRab2%2FGhn3tyWNQl6&amp;TOPIC_ID=6132" target="_blank">www.renalgenes.org</a> and <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fgtr&amp;token=ODIqmPyH03K5IrNHL4oottyJV%2BtPhS7Gs3UPQx%2BHe7XVbMNS34%2FFmqUdqR4ciKrK&amp;TOPIC_ID=6132" target="_blank">www.ncbi.nlm.nih.gov/gtr</a>.</p><p>Prenatal diagnosis can be performed by direct genetic testing if the specific variants have been identified in an affected sibling.</p><p class="headingAnchor" id="H2758000913"><span class="h2">Kidney biopsy</span><span class="headingEndMark"> — </span>A kidney biopsy is performed in the following settings for a patient with clinical findings compatible with NPHP:</p><p class="bulletIndent1"><span class="glyph">●</span>Genetic testing is negative</p><p class="bulletIndent1"><span class="glyph">●</span>When genetic testing is not available and the clinical diagnosis remains uncertain</p><p></p><p>In these patients, the diagnosis of NPHP is made based on the clinical diagnosis and histologic findings of chronic tubulointerstitial changes with an irregular thickening and multilayering of the tubular basement membranes  (<a class="graphic graphic_picture graphicRef66242" href="/z/d/graphic/66242.html" rel="external">picture 2</a>) [<a href="#rid59">59</a>]. </p><p class="headingAnchor" id="H11"><span class="h1">DIFFERENTIAL DIAGNOSIS</span><span class="headingEndMark"> — </span>The presence of the associated extra-renal findings (eg, retinitis pigmentosa) differentiates NPHP from the following chronic kidney disorders that present with a "bland" urine sediment (eg, no evidence of hematuria, cellular elements, or absence of proteinuria or mild tubular proteinuria) (see <a class="local">'Extrarenal manifestations'</a> above). However, in cases where extra-renal findings are absent, NPHP can be distinguished from these other conditions using a variety of diagnostic tools, including genetic testing, positive family history, renal imaging, and kidney biopsy.</p><p class="bulletIndent1"><span class="glyph">●</span>Obstructive uropathy – Presence of hydronephrosis on renal imaging is suggestive of obstructive uropathy and is not usually present in NPHP. However, a large bladder may be observed in patients with NPHP due to chronic polyuria. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Genetic ciliopathies resulting in cyst formation in children include early onset autosomal dominant polycystic kidney disease (ADPKD) and autosomal recessive polycystic kidney disease (ARPKD). These two disorders are often in the differential diagnosis for patients with the infantile form of NPHP. The diagnosis for either ADPKD or ARPKD is straightforward when there is a positive family history, including screening parents for ADPKD. Renal imaging may be equivocal in differentiating amongst these entities. In the setting where no family history is present and renal imaging is equivocal, genetic testing is performed to make a definitive diagnosis. (See  <a class="medical medical_review" href="/z/d/html/6138.html" rel="external">"Autosomal recessive polycystic kidney disease in children"</a> and  <a class="medical medical_review" href="/z/d/html/15319.html" rel="external">"Autosomal dominant polycystic kidney disease (ADPKD) in children"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Renal hypodysplasia – The presence of significantly smaller kidneys on renal ultrasonography (reduction by greater than two standard deviations) usually will differentiate renal hypodysplasia from NPHP with normal or slightly smaller kidneys. Renal hypodysplasia is observed in over 200 syndromic disorders where anomalies involving other organs are present. As a result, nonrenal findings not associated with NPHP would also be helpful in differentiating between these two disorders. (See  <a class="medical medical_review" href="/z/d/html/6083.html" rel="external">"Renal hypodysplasia"</a>.)</p><p></p><p class="headingAnchor" id="H12"><span class="h1">MANAGEMENT</span><span class="headingEndMark"> — </span>There is no specific therapy for NPHP. </p><p>Interventions include:</p><p class="bulletIndent1"><span class="glyph">●</span>Replacing ongoing water needs to prevent episodes of hypovolemia and providing adequate salt intake, especially during intercurrent illnesses that may alter the fluid and electrolyte needs and status.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Administration of erythropoietin and iron to patients with anemia. (See  <a class="medical medical_review" href="/z/d/html/128353.html" rel="external">"Chronic kidney disease in children: Complications", section on 'Anemia'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Providing active vitamin D analogues supplementation and phosphate binder to patients with evidence of secondary hyperparathyroidism. (See  <a class="medical medical_review" href="/z/d/html/6092.html" rel="external">"Pediatric chronic kidney disease-mineral and bone disorder (CKD-MBD)", section on 'Management'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Administration of growth hormone to patients with growth retardation. (See  <a class="medical medical_review" href="/z/d/html/6140.html" rel="external">"Growth failure in children with chronic kidney disease: Treatment with growth hormone"</a>.)</p><p></p><p>Patients with NPHP uniformly progress to end-stage kidney disease (ESKD). Kidney transplantation is the preferred replacement therapy because the disease does not recur in a transplant. In a report from the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) Registry, patients with NPHP had better outcomes after kidney transplantation when compared with all other patients registered in the NAPRTCS database, especially for those who received living donor kidney transplants [<a href="#rid52">52</a>]. </p><p>Using cell culture and in vivo models, prostaglandin E2 receptor agonists have been shown to ameliorate several of the pleotropic phenotypes caused by the absence of NPHP1 [<a href="#rid60">60</a>]. This may be a future potential therapeutic option in NPHP-RC; clinical data are lacking.</p><p class="headingAnchor" id="H13"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Etiology</strong> – Nephronophthisis (NPHP) is the result of gene variants that encode proteins involved in the function of primary cilia, basal bodies, or centrosomes. (See  <a class="medical medical_review" href="/z/d/html/6136.html" rel="external">"Genetics and pathogenesis of nephronophthisis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – NPHP is characterized by impaired urinary concentrating ability, a bland urinalysis (no proteinuria or mild tubular proteinuria, no hematuria or cellular elements), chronic tubulointerstitial disease, and progression to end-stage kidney disease (ESKD) generally by 20 years of age. Variants have been described based upon the median age of onset of ESKD  (<a class="graphic graphic_table graphicRef128963" href="/z/d/graphic/128963.html" rel="external">table 1</a>). These variants are associated with specific gene defects. (See <a class="local">'Renal disease'</a> above and  <a class="medical medical_review" href="/z/d/html/6136.html" rel="external">"Genetics and pathogenesis of nephronophthisis", section on 'Genetics'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The <strong>infantile</strong> form (median onset of ESKD by one year of age) is associated with variants in the <em>NPHP2</em> and <em>NPHP3</em> genes. Patients typically have large kidneys with large cysts and are more likely than other variants to have extra-renal abnormalities. (See <a class="local">'Infantile'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The <strong>juvenile</strong> form (median onset of ESKD is 13 years of age) is the most common variant. It is associated with variants in all the <em>NPHP</em> genes except <em>NPHP2</em>. These patients initially present with symptoms of polyuria and polydipsia due to impaired urinary concentration, anemia, and short stature, prior to a significant decline in kidney function and subsequent progression to ESKD. These patients typically have a "bland" urinalysis without evidence of hematuria or cellular elements. Ultrasonography demonstrates normal or slightly decreased-in-size kidneys with increased echogenicity and loss of corticomedullary differentiation. (See <a class="local">'Juvenile'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The <strong>adolescent</strong> form (median onset of ESKD by 19 years of age) is associated with variants in the <em>NPHP3</em> genes. Patients also exhibit initial symptoms of polyuria and polydipsia due to reduced urinary concentrating ability but at a later age than those with the juvenile variant. (See <a class="local">'Adolescent'</a> above.)</p><p></p><p class="bulletIndent1">Overall, extra-renal manifestations are observed in 20 percent of patients with NPHP. They include retinitis pigmentosa, skeletal defects, hepatic fibrosis, neurologic abnormalities, and cardiac defects. (See <a class="local">'Extrarenal manifestations'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Associated syndromes</strong> – The term NPHP-related ciliopathies (NPHP-RC) is used for the group of autosomal-recessive cystic kidney diseases which include nephronophthisis, including: Senior-Loken (retinitis pigmentosa), Joubert (cerebellar vermis hypoplasia  (<a class="graphic graphic_diagnosticimage graphicRef74695" href="/z/d/graphic/74695.html" rel="external">image 2</a>)), Meckel-Gruber (occipital encephalocele), and Sensenbrenner syndromes (skeletal anomalies), and asphyxiating thoracic dystrophy (ATD, also known as Jeune syndrome). (See <a class="local">'Associated syndromes'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Diagnosis</strong> – The diagnosis of NPHP is suspected by characteristic clinical findings and confirmed by a genetic testing. In the absence of a positive gene test, a kidney biopsy demonstrating chronic tubulointerstitial changes with a thickening of tubular basement membranes is suggestive of the diagnosis. (See <a class="local">'Diagnosis'</a> above and  <a class="medical medical_review" href="/z/d/html/6136.html" rel="external">"Genetics and pathogenesis of nephronophthisis", section on 'Pathology'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Differential diagnosis</strong> – The differential diagnosis for NPHP includes other chronic kidney disorders with a bland urinalysis. These disorders include renal hypodysplasia, urinary tract obstruction, and autosomal dominant and autosomal recessive polycystic kidney disease (ADPKD and ARPKD). The presence of associated extra-renal findings is useful to differentiate NPHP from these conditions. When extra-renal manifestations are absent, a variety of diagnostic tools, including renal imaging, genetic testing, and family history are used to distinguish NPHP. (See <a class="local">'Differential diagnosis'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Management</strong> – There is no specific treatment for NPHP. Management of children in the early stage of the disease without kidney function impairment is supportive focused on maintaining fluid and electrolyte balance, treating anemia and growth promotion. For patients with ESKD, we recommend kidney transplantation as the preferred renal replacement therapy (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). The outcome of kidney transplantation is excellent, as tubular injury does not recur in the transplanted kidney. (See <a class="local">'Management'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Srivastava S, Sayer JA. Nephronophthisis. J Pediatr Genet 2014; 3:103.</a></li><li><a class="nounderline abstract_t">Srivastava S, Molinari E, Raman S, Sayer JA. Many Genes-One Disease? Genetics of Nephronophthisis (NPHP) and NPHP-Associated Disorders. Front Pediatr 2017; 5:287.</a></li><li><a class="nounderline abstract_t">Hildebrandt F, Strahm B, Nothwang HG, et al. Molecular genetic identification of families with juvenile nephronophthisis type 1: rate of progression to renal failure. APN Study Group. Arbeitsgemeinschaft für Pädiatrische Nephrologie. Kidney Int 1997; 51:261.</a></li><li><a class="nounderline abstract_t">Simms RJ, Hynes AM, Eley L, Sayer JA. Nephronophthisis: a genetically diverse ciliopathy. Int J Nephrol 2011; 2011:527137.</a></li><li><a class="nounderline abstract_t">Hildebrandt F, Waldherr R, Kutt R, Brandis M. The nephronophthisis complex: clinical and genetic aspects. Clin Investig 1992; 70:802.</a></li><li><a class="nounderline abstract_t">Hildebrandt F, Attanasio M, Otto E. Nephronophthisis: disease mechanisms of a ciliopathy. J Am Soc Nephrol 2009; 20:23.</a></li><li><a class="nounderline abstract_t">Chaki M, Hoefele J, Allen SJ, et al. Genotype-phenotype correlation in 440 patients with NPHP-related ciliopathies. Kidney Int 2011; 80:1239.</a></li><li><a class="nounderline abstract_t">König J, Kranz B, König S, et al. Phenotypic Spectrum of Children with Nephronophthisis and Related Ciliopathies. Clin J Am Soc Nephrol 2017; 12:1974.</a></li><li><a class="nounderline abstract_t">Burke JR, Inglis JA, Craswell PW, et al. Juvenile nephronophthisis and medullary cystic disease--the same disease (report of a large family with medullary cystic disease associated with gout and epilepsy). Clin Nephrol 1982; 18:1.</a></li><li><a class="nounderline abstract_t">Hoefele J, Nayir A, Chaki M, et al. Pseudodominant inheritance of nephronophthisis caused by a homozygous NPHP1 deletion. Pediatr Nephrol 2011; 26:967.</a></li><li><a class="nounderline abstract_t">Georges B, Cosyns JP, Dahan K, et al. Late-onset renal failure in Senior-Loken syndrome. Am J Kidney Dis 2000; 36:1271.</a></li><li><a class="nounderline abstract_t">Stokman MF, van der Zwaag B, van de Kar NCAJ, et al. Clinical and genetic analyses of a Dutch cohort of 40 patients with a nephronophthisis-related ciliopathy. Pediatr Nephrol 2018; 33:1701.</a></li><li><a class="nounderline abstract_t">König JC, Karsay R, Gerß J, et al. Refining Kidney Survival in 383 Genetically Characterized Patients With Nephronophthisis. Kidney Int Rep 2022; 7:2016.</a></li><li><a class="nounderline abstract_t">Haider NB, Carmi R, Shalev H, et al. A Bedouin kindred with infantile nephronophthisis demonstrates linkage to chromosome 9 by homozygosity mapping. Am J Hum Genet 1998; 63:1404.</a></li><li><a class="nounderline abstract_t">Otto EA, Schermer B, Obara T, et al. Mutations in INVS encoding inversin cause nephronophthisis type 2, linking renal cystic disease to the function of primary cilia and left-right axis determination. Nat Genet 2003; 34:413.</a></li><li><a class="nounderline abstract_t">Gagnadoux MF, Bacri JL, Broyer M, Habib R. Infantile chronic tubulo-interstitial nephritis with cortical microcysts: variant of nephronophthisis or new disease entity? Pediatr Nephrol 1989; 3:50.</a></li><li><a class="nounderline abstract_t">Oud MM, van Bon BW, Bongers EM, et al. Early presentation of cystic kidneys in a family with a homozygous INVS mutation. Am J Med Genet A 2014; 164A:1627.</a></li><li><a class="nounderline abstract_t">Tory K, Rousset-Rouvière C, Gubler MC, et al. Mutations of NPHP2 and NPHP3 in infantile nephronophthisis. Kidney Int 2009; 75:839.</a></li><li><a class="nounderline abstract_t">Bodaghi E, Honarmand MT, Ahmadi M. Infantile nephronophthisis. Int J Pediatr Nephrol 1987; 8:207.</a></li><li><a class="nounderline abstract_t">Ala-Mello S, Kivivuori SM, Rönnholm KA, et al. Mechanism underlying early anaemia in children with familial juvenile nephronophthisis. Pediatr Nephrol 1996; 10:578.</a></li><li><a class="nounderline abstract_t">Blowey DL, Querfeld U, Geary D, et al. Ultrasound findings in juvenile nephronophthisis. Pediatr Nephrol 1996; 10:22.</a></li><li><a class="nounderline abstract_t">Garel LA, Habib R, Pariente D, et al. Juvenile nephronophthisis: sonographic appearance in children with severe uremia. Radiology 1984; 151:93.</a></li><li><a class="nounderline abstract_t">Olbrich H, Fliegauf M, Hoefele J, et al. Mutations in a novel gene, NPHP3, cause adolescent nephronophthisis, tapeto-retinal degeneration and hepatic fibrosis. Nat Genet 2003; 34:455.</a></li><li><a class="nounderline abstract_t">Omran H, Fernandez C, Jung M, et al. Identification of a new gene locus for adolescent nephronophthisis, on chromosome 3q22 in a large Venezuelan pedigree. Am J Hum Genet 2000; 66:118.</a></li><li><a class="nounderline abstract_t">McConnachie DJ, Stow JL, Mallett AJ. Ciliopathies and the Kidney: A Review. Am J Kidney Dis 2021; 77:410.</a></li><li><a class="nounderline abstract_t">Mainzer F, Saldino RM, Ozonoff MB, Minagi H. Familial nephropathy associatdd with retinitis pigmentosa, cerebellar ataxia and skeletal abnormalities. Am J Med 1970; 49:556.</a></li><li><a class="nounderline abstract_t">Betz R, Rensing C, Otto E, et al. Children with ocular motor apraxia type Cogan carry deletions in the gene (NPHP1) for juvenile nephronophthisis. J Pediatr 2000; 136:828.</a></li><li><a class="nounderline abstract_t">Sayer JA, Otto EA, O'Toole JF, et al. The centrosomal protein nephrocystin-6 is mutated in Joubert syndrome and activates transcription factor ATF4. Nat Genet 2006; 38:674.</a></li><li><a class="nounderline abstract_t">Boichis H, Passwell J, David R, Miller H. Congenital hepatic fibrosis and nephronophthisis. A family study. Q J Med 1973; 42:221.</a></li><li><a class="nounderline abstract_t">Proesmans W, Van Damme B, Macken J. Nephronophthisis and tapetoretinal degeneration associated with liver fibrosis. Clin Nephrol 1975; 3:160.</a></li><li><a class="nounderline abstract_t">Witzleben CL, Sharp AR. "Nephronophthisis-congenital hepatic fibrosis": an additional hepatorenal disorder. Hum Pathol 1982; 13:728.</a></li><li><a class="nounderline abstract_t">Otto EA, Tory K, Attanasio M, et al. Hypomorphic mutations in meckelin (MKS3/TMEM67) cause nephronophthisis with liver fibrosis (NPHP11). J Med Genet 2009; 46:663.</a></li><li><a class="nounderline abstract_t">Hoff S, Halbritter J, Epting D, et al. ANKS6 is a central component of a nephronophthisis module linking NEK8 to INVS and NPHP3. Nat Genet 2013; 45:951.</a></li><li><a class="nounderline abstract_t">Schueler M, Braun DA, Chandrasekar G, et al. DCDC2 mutations cause a renal-hepatic ciliopathy by disrupting Wnt signaling. Am J Hum Genet 2015; 96:81.</a></li><li><a class="nounderline abstract_t">Bergmann C, Fliegauf M, Brüchle NO, et al. Loss of nephrocystin-3 function can cause embryonic lethality, Meckel-Gruber-like syndrome, situs inversus, and renal-hepatic-pancreatic dysplasia. Am J Hum Genet 2008; 82:959.</a></li><li><a class="nounderline abstract_t">Wolf MT. Nephronophthisis and related syndromes. Curr Opin Pediatr 2015; 27:201.</a></li><li><a class="nounderline abstract_t">SENIOR B, FRIEDMANN AI, BRAUDO JL. Juvenile familial nephropathy with tapetoretinal degeneration. A new oculorenal dystrophy. Am J Ophthalmol 1961; 52:625.</a></li><li><a class="nounderline abstract_t">LOKEN AC, HANSSEN O, HALVORSEN S, JOLSTER NJ. Hereditary renal dysplasia and blindness. Acta Paediatr 1961; 50:177.</a></li><li><a class="nounderline abstract_t">Otto EA, Loeys B, Khanna H, et al. Nephrocystin-5, a ciliary IQ domain protein, is mutated in Senior-Loken syndrome and interacts with RPGR and calmodulin. Nat Genet 2005; 37:282.</a></li><li><a class="nounderline abstract_t">Caridi G, Dagnino M, Gusmano R, et al. Clinical and molecular heterogeneity of juvenile nephronophthisis in Italy: insights from molecular screening. Am J Kidney Dis 2000; 35:44.</a></li><li><a class="nounderline abstract_t">Caridi G, Murer L, Bellantuono R, et al. Renal-retinal syndromes: association of retinal anomalies and recessive nephronophthisis in patients with homozygous deletion of the NPH1 locus. Am J Kidney Dis 1998; 32:1059.</a></li><li><a class="nounderline abstract_t">Caridi G, Dagnino M, Rossi A, et al. Nephronophthisis type 1 deletion syndrome with neurological symptoms: prevalence and significance of the association. Kidney Int 2006; 70:1342.</a></li><li><a class="nounderline abstract_t">Parisi MA, Bennett CL, Eckert ML, et al. The NPHP1 gene deletion associated with juvenile nephronophthisis is present in a subset of individuals with Joubert syndrome. Am J Hum Genet 2004; 75:82.</a></li><li><a class="nounderline abstract_t">Tory K, Lacoste T, Burglen L, et al. High NPHP1 and NPHP6 mutation rate in patients with Joubert syndrome and nephronophthisis: potential epistatic effect of NPHP6 and AHI1 mutations in patients with NPHP1 mutations. J Am Soc Nephrol 2007; 18:1566.</a></li><li><a class="nounderline abstract_t">Castori M, Valente EM, Donati MA, et al. NPHP1 gene deletion is a rare cause of Joubert syndrome related disorders. J Med Genet 2005; 42:e9.</a></li><li><a class="nounderline abstract_t">Arts HH, Doherty D, van Beersum SE, et al. Mutations in the gene encoding the basal body protein RPGRIP1L, a nephrocystin-4 interactor, cause Joubert syndrome. Nat Genet 2007; 39:882.</a></li><li><a class="nounderline abstract_t">Valente EM, Logan CV, Mougou-Zerelli S, et al. Mutations in TMEM216 perturb ciliogenesis and cause Joubert, Meckel and related syndromes. Nat Genet 2010; 42:619.</a></li><li><a class="nounderline abstract_t">Davis EE, Zhang Q, Liu Q, et al. TTC21B contributes both causal and modifying alleles across the ciliopathy spectrum. Nat Genet 2011; 43:189.</a></li><li><a class="nounderline abstract_t">Huber C, Cormier-Daire V. Ciliary disorder of the skeleton. Am J Med Genet C Semin Med Genet 2012; 160C:165.</a></li><li><a class="nounderline abstract_t">Heninger E, Otto E, Imm A, et al. Improved strategy for molecular genetic diagnostics in juvenile nephronophthisis. Am J Kidney Dis 2001; 37:1131.</a></li><li><a class="nounderline abstract_t">Stavrou C, Deltas CC, Christophides TC, Pierides A. Outcome of kidney transplantation in autosomal dominant medullary cystic kidney disease type 1. Nephrol Dial Transplant 2003; 18:2165.</a></li><li><a class="nounderline abstract_t">Hamiwka LA, Midgley JP, Wade AW, et al. Outcomes of kidney transplantation in children with nephronophthisis: an analysis of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) Registry. Pediatr Transplant 2008; 12:878.</a></li><li><a class="nounderline abstract_t">Radha Rama Devi A, Naushad SM, Lingappa L. Clinical and Molecular Diagnosis of Joubert Syndrome and Related Disorders. Pediatr Neurol 2020; 106:43.</a></li><li><a class="nounderline abstract_t">Harris CM, Hodgkins PR, Kriss A, et al. Familial congenital saccade initiation failure and isolated cerebellar vermis hypoplasia. Dev Med Child Neurol 1998; 40:775.</a></li><li><a class="nounderline abstract_t">Delous M, Baala L, Salomon R, et al. The ciliary gene RPGRIP1L is mutated in cerebello-oculo-renal syndrome (Joubert syndrome type B) and Meckel syndrome. Nat Genet 2007; 39:875.</a></li><li><a class="nounderline abstract_t">Baala L, Romano S, Khaddour R, et al. The Meckel-Gruber syndrome gene, MKS3, is mutated in Joubert syndrome. Am J Hum Genet 2007; 80:186.</a></li><li><a class="nounderline abstract_t">Halbritter J, Porath JD, Diaz KA, et al. Identification of 99 novel mutations in a worldwide cohort of 1,056 patients with a nephronophthisis-related ciliopathy. Hum Genet 2013; 132:865.</a></li><li><a class="nounderline abstract_t">Braun DA, Schueler M, Halbritter J, et al. Whole exome sequencing identifies causative mutations in the majority of consanguineous or familial cases with childhood-onset increased renal echogenicity. Kidney Int 2016; 89:468.</a></li><li><a class="nounderline abstract_t">Steele BT, Lirenman DS, Beattie CW. Nephronophthisis. Am J Med 1980; 68:531.</a></li><li><a class="nounderline abstract_t">Garcia H, Serafin AS, Silbermann F, et al. Agonists of prostaglandin E2 receptors as potential first in class treatment for nephronophthisis and related ciliopathies. Proc Natl Acad Sci U S A 2022; 119:e2115960119.</a></li></ol></div><div id="topicVersionRevision">Topic 6132 Version 31.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27625867" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Nephronophthisis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29379777" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Many Genes-One Disease? Genetics of Nephronophthisis (NPHP) and NPHP-Associated Disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8995741" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Molecular genetic identification of families with juvenile nephronophthisis type 1: rate of progression to renal failure. APN Study Group. Arbeitsgemeinschaft für Pädiatrische Nephrologie.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21660307" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Nephronophthisis: a genetically diverse ciliopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1450635" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : The nephronophthisis complex: clinical and genetic aspects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19118152" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Nephronophthisis: disease mechanisms of a ciliopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21866095" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Genotype-phenotype correlation in 440 patients with NPHP-related ciliopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29146700" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Phenotypic Spectrum of Children with Nephronophthisis and Related Ciliopathies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7116701" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Juvenile nephronophthisis and medullary cystic disease--the same disease (report of a large family with medullary cystic disease associated with gout and epilepsy).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21258817" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Pseudodominant inheritance of nephronophthisis caused by a homozygous NPHP1 deletion.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11096053" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Late-onset renal failure in Senior-Loken syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29974258" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Clinical and genetic analyses of a Dutch cohort of 40 patients with a nephronophthisis-related ciliopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36090483" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Refining Kidney Survival in 383 Genetically Characterized Patients With Nephronophthisis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9792867" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : A Bedouin kindred with infantile nephronophthisis demonstrates linkage to chromosome 9 by homozygosity mapping.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12872123" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Mutations in INVS encoding inversin cause nephronophthisis type 2, linking renal cystic disease to the function of primary cilia and left-right axis determination.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2702088" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Infantile chronic tubulo-interstitial nephritis with cortical microcysts: variant of nephronophthisis or new disease entity?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24677454" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Early presentation of cystic kidneys in a family with a homozygous INVS mutation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19177160" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Mutations of NPHP2 and NPHP3 in infantile nephronophthisis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3449470" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Infantile nephronophthisis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8897559" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Mechanism underlying early anaemia in children with familial juvenile nephronophthisis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8611349" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Ultrasound findings in juvenile nephronophthisis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6701346" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Juvenile nephronophthisis: sonographic appearance in children with severe uremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12872122" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Mutations in a novel gene, NPHP3, cause adolescent nephronophthisis, tapeto-retinal degeneration and hepatic fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10631142" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Identification of a new gene locus for adolescent nephronophthisis, on chromosome 3q22 in a large Venezuelan pedigree.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33039432" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Ciliopathies and the Kidney: A Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4991086" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Familial nephropathy associatdd with retinitis pigmentosa, cerebellar ataxia and skeletal abnormalities.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10839884" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Children with ocular motor apraxia type Cogan carry deletions in the gene (NPHP1) for juvenile nephronophthisis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16682973" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : The centrosomal protein nephrocystin-6 is mutated in Joubert syndrome and activates transcription factor ATF4.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4688793" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Congenital hepatic fibrosis and nephronophthisis. A family study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1149338" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Nephronophthisis and tapetoretinal degeneration associated with liver fibrosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7106736" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : "Nephronophthisis-congenital hepatic fibrosis": an additional hepatorenal disorder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19508969" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Hypomorphic mutations in meckelin (MKS3/TMEM67) cause nephronophthisis with liver fibrosis (NPHP11).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23793029" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : ANKS6 is a central component of a nephronophthisis module linking NEK8 to INVS and NPHP3.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25557784" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : DCDC2 mutations cause a renal-hepatic ciliopathy by disrupting Wnt signaling.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18371931" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Loss of nephrocystin-3 function can cause embryonic lethality, Meckel-Gruber-like syndrome, situs inversus, and renal-hepatic-pancreatic dysplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25635582" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Nephronophthisis and related syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13910672" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Juvenile familial nephropathy with tapetoretinal degeneration. A new oculorenal dystrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13763238" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Hereditary renal dysplasia and blindness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15723066" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Nephrocystin-5, a ciliary IQ domain protein, is mutated in Senior-Loken syndrome and interacts with RPGR and calmodulin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10620543" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Clinical and molecular heterogeneity of juvenile nephronophthisis in Italy: insights from molecular screening.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9856524" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Renal-retinal syndromes: association of retinal anomalies and recessive nephronophthisis in patients with homozygous deletion of the NPH1 locus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16900087" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Nephronophthisis type 1 deletion syndrome with neurological symptoms: prevalence and significance of the association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15138899" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : The NPHP1 gene deletion associated with juvenile nephronophthisis is present in a subset of individuals with Joubert syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17409309" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : High NPHP1 and NPHP6 mutation rate in patients with Joubert syndrome and nephronophthisis: potential epistatic effect of NPHP6 and AHI1 mutations in patients with NPHP1 mutations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15689444" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : NPHP1 gene deletion is a rare cause of Joubert syndrome related disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17558407" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Mutations in the gene encoding the basal body protein RPGRIP1L, a nephrocystin-4 interactor, cause Joubert syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20512146" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Mutations in TMEM216 perturb ciliogenesis and cause Joubert, Meckel and related syndromes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21258341" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : TTC21B contributes both causal and modifying alleles across the ciliopathy spectrum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22791528" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Ciliary disorder of the skeleton.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11382680" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Improved strategy for molecular genetic diagnostics in juvenile nephronophthisis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13679497" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Outcome of kidney transplantation in autosomal dominant medullary cystic kidney disease type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19000067" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Outcomes of kidney transplantation in children with nephronophthisis: an analysis of the North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS) Registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32139166" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Clinical and Molecular Diagnosis of Joubert Syndrome and Related Disorders.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9881808" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Familial congenital saccade initiation failure and isolated cerebellar vermis hypoplasia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17558409" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : The ciliary gene RPGRIP1L is mutated in cerebello-oculo-renal syndrome (Joubert syndrome type B) and Meckel syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17160906" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : The Meckel-Gruber syndrome gene, MKS3, is mutated in Joubert syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23559409" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Identification of 99 novel mutations in a worldwide cohort of 1,056 patients with a nephronophthisis-related ciliopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26489029" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Whole exome sequencing identifies causative mutations in the majority of consanguineous or familial cases with childhood-onset increased renal echogenicity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7369232" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Nephronophthisis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35482924" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Agonists of prostaglandin E2 receptors as potential first in class treatment for nephronophthisis and related ciliopathies.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
